XML 19 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Changes in Equity - EUR (€)
€ in Millions
Total
Attributable to equity holders of Sanofi
Share capital
Additional paid-in capital
Treasury shares
Reserves and retained earnings
Stock options and other share-based payments
Other comprehensive income
Attributable to non-controlling interests
Beginning balance at Dec. 31, 2021 € 69,031 € 68,681 € 2,527 € 532 € (939) € 63,013 € 4,405 € (857) € 350
Other comprehensive income for the period 4,250 4,231       787   3,444 19
Net income for the period 3,237 3,184       3,184     53
Comprehensive income 7,487 7,415       3,971   3,444 72
Dividend paid out of earnings (4,168) (4,168)       (4,168)      
Effect of the distribution of an exceptional supplementary dividend of 58% of the shares of EUROAPI to the equity holders of Sanofi [1] (793) (793)       (793)      
Payment of dividends to non-controlling interests (69) 0             (69)
Share repurchase program [2] (360) (360)     (360)        
Share-based payment plans:                  
Exercise of stock options 27 27 1 26          
Issuance of restricted shares and vesting of existing restricted shares 0 0 3 (3) 130 (130)      
Value of services obtained from employees 144 144         144    
Tax effects of the exercise of stock options 15 15         15    
Other movements (10) (10)       (10)      
Ending balance at Jun. 30, 2022 71,304 70,951 2,531 555 (1,169) 61,883 4,564 2,587 353
Beginning balance at Dec. 31, 2021 69,031 68,681 2,527 532 (939) 63,013 4,405 (857) 350
Other comprehensive income for the period 2,764                
Net income for the period 8,484                
Comprehensive income 11,248                
Ending balance at Dec. 31, 2022 75,152 74,784 2,522 125 (706) 66,734 4,658 1,451 368
Beginning balance at Jun. 30, 2022 71,304 70,951 2,531 555 (1,169) 61,883 4,564 2,587 353
Other comprehensive income for the period (1,486) (1,472)       (336)   (1,136) (14)
Net income for the period 5,247 5,187       5,187     60
Comprehensive income 3,761 3,715       4,851   (1,136) 46
Payment of dividends to non-controlling interests (31)               (31)
Share repurchase program [2] (137) (137)     (137)        
Reductions in share capital 0 0 (13) (587) 600        
Share-based payment plans:                  
Exercise of stock options 8 8   8          
Employee share ownership plan 153 153 4 149          
Value of services obtained from employees 101 101         101    
Tax effects of the exercise of stock options (7) (7)         (7)    
Ending balance at Dec. 31, 2022 75,152 74,784 2,522 125 (706) 66,734 4,658 1,451 368
Other comprehensive income for the period (973) (965)       85   (1,050) (8)
Net income for the period 3,456 3,430       3,430     26
Comprehensive income 2,483 2,465       3,515   (1,050) 18
Dividend paid out of earnings (4,454) (4,454)       (4,454)      
Payment of dividends to non-controlling interests (49) 0             (49)
Share repurchase program [2] (363) (363)     (363)        
Share-based payment plans:                  
Exercise of stock options 18 18   18          
Issuance of restricted shares and vesting of existing restricted shares [2] 0 0 3 (3) 112 (112)      
Value of services obtained from employees 160 160         160    
Tax effects of the exercise of stock options 8 8         8    
Other changes arising from issuance of restricted shares [3] 2 2       2      
Other movements [4] (10) 9       9     (19)
Ending balance at Jun. 30, 2023 € 72,947 € 72,629 € 2,525 € 140 € (957) € 65,694 € 4,826 € 401 € 318
[1] See Note D.1. to the consolidated financial statements for the year ended December 31, 2022
[2] See Note B.8.2. (for amounts relating to 2022, see Note D.1.5.4. to the consolidated financial statements for the year ended December 31, 2022).
[3] This line comprises the impact of issuance of restricted shares to former employees of EUROAPI subsequent to the date on which Sanofi ceased to have control over EUROAPI.
[4] This line mainly comprises the impact on non-controlling interests arising from divestments and acquisitions.